Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Immunovant Reports Q4 Loss, Analysts Raise Price Targets on Buy Ratings

May 21, 2026, 12:31 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The wider-than-expected loss typically indicates poor performance; however, raised price targets can provide a cushion for the stock.

AI summary

What happened, with direct paths to the underlying reporting

Immunovant (IMVT) reported a wider-than-expected quarterly loss, leading to a 5% drop in share price. However, analysts from HC Wainwright and B of A Securities maintained their Buy ratings and increased their price targets, indicating potential for recovery.

Immunovant reported Q4 loss of $0.73, missing estimates of $0.60.
R&D expenses rose to $142.3 million, largely due to IMVT-1402 trials.
Full-year R&D costs increased to $426.9 million from $333.9 million.
Shares dropped 5% to $33.76 following earnings announcement.
Analysts raised price targets, maintaining Buy ratings despite losses.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Immunovant Reports Q4 Loss, Analysts Raise Price Targets on Buy Ratings

Immunovant Reports Strong Trial Results Amid Wider Losses

Immunovant's muscle disorder treatment meets main goal in late-stage trial